The Clinical And Immune Effect Of Chemotherapy Combined With Dendritic Cells Co-cultured With Cytokine-induced Killer Cells In The Treatment Of Advanced Lung Cancer

Objective:To investigate whether DC-CIK(Dendritic Cells Co-Cultured with CytokineInduced Killer Cells)combined with chemotherapy can improve the clinical and immunological efficacy of advanced lung cancer patients.MethodsWe retrospectively analyzed 60 cases of advanced lung cancer patients in the second department of medicine in Jiangxi Tumor Hospital.It can be divided into two treatment groups: DC-CIK combined chemotherapy group and pure chemotherapy treatment group,30 cases in each group.The conventional chemotherapy regimens along with DC-CIK cells immunotherapy were used in DC-CIK combined chemotherapy group at the same time.Only the conventional chemotherapy regimens were used in pure chemotherapy treatment group.We observed the patients in the two groups of recent effects(ORR,DCR),the change of T lymphocyte subsets,and adverse events after treatment,etc.Results1)There was no significant difference between the two groups before treatment,including gender,age,stage,pathological type,Karnofsky score and so on(P > 0.05).2)The disease control rate(DCR)of DC-CIK combined chemotherapy group was 70%,and pure chemotherapy treatment group was53.33%.The objective response rate(ORR)of the two groups was both 16.7%,there both were no statistically significant difference(P > 0.05).3)In immunological test,the CD3~+T lymphocyte count,CD4~+T lymphocyte count and CD8~+T lymphocyte count increased significantly after treatment in DC-CIK combined chemotherapy group with statistical difference(P < 0.05);CD4~+ /CD8~+ratio also rised,but there was no statistically significant difference(P > 0.05).4)While in pure chemotherapy group,the CD3~+T lymphocyte count and CD8~+T lymphocyte count after chemo-therapy was higher than that before treatment,but there was no statistically significant difference(P > 0.05);Compared with before chemotherapy CD4~+T lymphocyte count and CD4~+/ CD8~+ratio went down but there was no statistically significant difference(P > 0.05).5)Compared the two groups of patients,there were no statistical differences of immunological examinations before treatment.After treatment,the CD3~+T lymphocyte count,CD4~+ lymphocyte count and CD8~+ T lymphocyte count in DC-CIK combined chemotherapy group rised significantly compared with those in pure chemotherapy group,and the difference was statistically significant(P < 0.05).;CD4~+ / CD8~+ ratio also rised,but there was no statistically significant difference(P >0.05).6)Compared the two groups of patients,after treatment,the incidence of nausea and vomiting in DC-CIK combined treatment group(26.67%)was significantly lower than that in the pure chemotherapy group(60%)(P < 0.05).But the incidence of adverse events including leukopenia,thrombocytopenia,bone marrow suppression,liver and kidney function damage between the two groups of patients after treatment showed no significant differences(P > 0.05).7)There were no significant changes in CEA and NSE levels before and after treatment in the two groups(P > 0.05).ConclusionsDC-CIK combined chemotherapy could effectively increase the CD3~+T lymphocyte count,CD4~+T lymphocyte count and CD8~+T lymphocyte count,and cause less adverse events in the advanced lung cancer patient.It can be used as a treatment for patients with advanced lung cancer.